PDT Partners LLC Purchases 41,641 Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

PDT Partners LLC grew its stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 28.3% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 188,803 shares of the company's stock after purchasing an additional 41,641 shares during the period. PDT Partners LLC owned about 0.33% of Ginkgo Bioworks worth $1,854,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Forbes J M & Co. LLP increased its holdings in Ginkgo Bioworks by 461.4% during the fourth quarter. Forbes J M & Co. LLP now owns 701,732 shares of the company's stock worth $6,891,000 after buying an additional 576,732 shares during the last quarter. Erste Asset Management GmbH grew its position in shares of Ginkgo Bioworks by 47.9% during the 4th quarter. Erste Asset Management GmbH now owns 739,332 shares of the company's stock valued at $6,979,000 after acquiring an additional 239,332 shares during the period. Susquehanna Fundamental Investments LLC purchased a new position in shares of Ginkgo Bioworks during the 4th quarter valued at $1,796,000. Schonfeld Strategic Advisors LLC purchased a new stake in Ginkgo Bioworks during the fourth quarter valued at about $1,000,000. Finally, Prescott Group Capital Management L.L.C. increased its stake in shares of Ginkgo Bioworks by 33.1% in the fourth quarter. Prescott Group Capital Management L.L.C. now owns 361,750 shares of the company's stock worth $3,552,000 after purchasing an additional 90,000 shares in the last quarter. 78.63% of the stock is owned by hedge funds and other institutional investors.

Ginkgo Bioworks Trading Up 1.1 %

Shares of DNA stock traded up $0.08 during trading on Friday, reaching $7.04. 1,049,317 shares of the company's stock traded hands, compared to its average volume of 1,478,624. Ginkgo Bioworks Holdings, Inc. has a 1 year low of $5.00 and a 1 year high of $41.20. The company has a market capitalization of $408.56 million, a P/E ratio of -0.54 and a beta of 1.34. The firm's 50-day moving average is $7.24 and its 200 day moving average is $9.13.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.